Why surveillance of antimicrobial resistance needs to be automated and comprehensive.


Journal

Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459

Informations de publication

Date de publication:
06 2019
Historique:
received: 23 01 2018
revised: 03 08 2018
accepted: 07 10 2018
pubmed: 17 10 2018
medline: 20 5 2020
entrez: 17 10 2018
Statut: ppublish

Résumé

Surveillance of antimicrobial resistance (AMR) can now be automated to analyse the reports of microbiology laboratories continually without operator assistance. It can also be made comprehensive to monitor all the reports of all the world's microbiology laboratories. As illustrated through examples provided in this work, each clinical report can be scanned automatically by algorithms to suspect emerging problems and to prompt sampling to confirm such problems, now increasingly by nucleotide sequencing. An emerging problem may be an excess (clustering) of similar microbes owing to their spread among patients who are interrelated in some way, as by shared locations, caregivers or food products. Or it might be a microbe new to an area or to a laboratory but already seen nearby, such as Elizabethkingia anophelis or mcr-1-positive Escherichia coli. Automated early alerting of responders enables them to contain spread sooner and to avert infections downstream. 'Big Data' informatics now also enables surveillance of AMR to be made comprehensive, to monitor all reports of all the world's microbiology laboratories. Such orders of magnitude increase in analysed data would accordingly increase its granularity and thus detect many more global problems sooner. It would also reduce surveillance-blind areas where problems may now emerge and spread undetected. The world's microbiology laboratories need to integrate and analyse all of their reports for surveillance to make their own patients safer from existing and approaching problems otherwise hard to notice. Making automated surveillance an easy-to-adopt laboratory standard of care can make it comprehensive.

Identifiants

pubmed: 30326273
pii: S2213-7165(18)30200-5
doi: 10.1016/j.jgar.2018.10.011
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0

Types de publication

Evaluation Study Journal Article Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

8-15

Subventions

Organisme : NCI NIH HHS
ID : U01 CA207167
Pays : United States
Organisme : NCEZID CDC HHS
ID : U54 CK000172
Pays : United States

Informations de copyright

Copyright © 2018. Published by Elsevier Ltd.

Auteurs

Thomas F O'Brien (TF)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Adam Clark (A)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

Rob Peters (R)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

John Stelling (J)

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. Electronic address: jstelling@whonet.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH